ArticleFrontiers in cardiovascular medicine2025
The burden of atrial fibrillation/atrial flutter in Europe from 1990 to 2021, with a forecast of incidence through 2044.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The objective of this analysis was to assess the impact of atrial fibrillation (AF)/atrial flutter (AFL) across various European regions and countries from 1990 to 2021. Methods: Using the global burden disease 2021 analytical tools, this study evaluated the incidence, prevalence, disability-adjusted life years (DALYs) and death associated with AF/AFL across the European Region, as defined by the World Health Organization, which includes 53 member countries (EU-53), as well as the European Union, as defined in 2019, consisting of 28 member countries (EU-28) from 1990 to 2021. Results: The EU-53, in 2021, there were 957,812 incident cases [95% uncertainty interval (UI): 773,898 to 1,178,186], 103,043 deaths (95% UI: 86,887 to 111,924), and 2,196,895 DALYs (95% UI: 1,847,967 to 2 596 530) attributed to AF/AFL. The age-standardized rates (ASRs) of incidence, prevalence, death, and DALYs were respectively 1.16, 1.14, 1.06, and 1.10 times higher in the EU-28 compared to the EU-53. The absolute number of AF/AFL incidents is projected to increase from 2021 to 2044 across Western Europe (from 600,735 to 723,218), Eastern Europe (from 176,794 to 190,803), and Central Europe (from 122,625 to 135,877). Conclusion: Despite substantial efforts to manage AF/AFL in Europe, it remains a significant public health challenge. The burden of AF/AFL varies considerably across European countries and subregions, as well as between different EU classifications (EU-28 vs. EU-53). In Western Europe and the EU-28, which include many developed nations, higher ASRs of deaths, DALYs, prevalence, and incidence have been reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.